theory clinical_102_1
imports Main

begin

typedecl entity
typedecl event

consts
  Lapatinib :: "entity ⇒ bool"
  Neratinib :: "entity ⇒ bool"
  HER2KinaseDomain :: "entity ⇒ bool"
  Tumors :: "entity ⇒ bool"
  Mutations :: "entity ⇒ bool"
  Bind :: "event ⇒ bool"
  Agent :: "event ⇒ entity ⇒ bool"
  Patient :: "event ⇒ entity ⇒ bool"  (* Corrected type *)
  Efficacy :: "event ⇒ bool"
  Against :: "event ⇒ entity ⇒ bool"
  Benefit :: "event ⇒ bool"
  Inhibitor :: "entity ⇒ bool"
  Irreversible :: "entity ⇒ bool"
  Targeted :: "event ⇒ bool"
  TreatmentResistance :: "entity ⇒ bool"
  Overcome :: "event ⇒ bool"
  Effective :: "event ⇒ bool"
  In :: "event ⇒ entity ⇒ bool"
  ERBB2V777L :: "entity ⇒ bool"
  ClinicalTrials :: "entity ⇒ bool"
  BreastCarcinoma :: "entity ⇒ bool"
  InclusionCriterion :: "entity ⇒ entity ⇒ bool"
  For :: "entity ⇒ entity ⇒ bool"
  Open :: "entity ⇒ bool"
  Closed :: "entity ⇒ bool"
  Patients :: "entity ⇒ bool"
  Access :: "event ⇒ bool"
  Trials :: "entity ⇒ bool"
  InclusionCriteria :: "entity ⇒ entity ⇒ entity ⇒ bool"
  Phase1or2 :: "entity ⇒ bool"
  Phase2 :: "entity ⇒ bool"
  Treatment :: "entity ⇒ bool"
  ClinicalTrial :: "entity ⇒ bool"

(* Explanation 1: Lapatinib and neratinib bind to the HER2 kinase domain and are therefore expected to have efficacy against tumors with these mutations in the kinase domain, which may benefit patients with such mutations. *)
axiomatization where
  explanation_1: "∃x y z w e1 e2 e3. Lapatinib x ∧ Neratinib y ∧ HER2KinaseDomain z ∧ Tumors w ∧ Mutations w ∧ Bind e1 ∧ Agent e1 x ∧ Agent e1 y ∧ Patient e1 z ∧ Efficacy e2 ∧ Agent e2 x ∧ Agent e2 y ∧ Against e2 w ∧ (Benefit e3 ∧ Agent e3 w ∧ Patient e3 z)"

(* Explanation 2: An irreversible inhibitor that is targeted to the HER2 kinase domain may overcome treatment resistance and be effective in breast cancer patients. *)
axiomatization where
  explanation_2: "∃x y z e1 e2. Inhibitor x ∧ Irreversible x ∧ HER2KinaseDomain y ∧ Targeted e1 ∧ Agent e1 x ∧ Patient e1 y ∧ TreatmentResistance z ∧ Overcome e2 ∧ Agent e2 x ∧ Patient e2 z ∧ Effective e2 ∧ In e2 z"

(* Explanation 3: ERBB2 V777L is an inclusion criterion in 4 clinical trials for breast carcinoma, of which 4 are open and 0 are closed. *)
axiomatization where
  explanation_3: "∃x y z. ERBB2V777L x ∧ ClinicalTrials y ∧ BreastCarcinoma z ∧ InclusionCriterion x y ∧ For y z ∧ Open y ∧ ¬Closed y"

(* Explanation 4: Patients with ERBB2 V777L may access these open clinical trials. *)
axiomatization where
  explanation_4: "∃x y z e. Patients x ∧ ERBB2V777L y ∧ ClinicalTrials z ∧ Open z ∧ Access e ∧ Agent e x ∧ Patient e z"

(* Explanation 5: Of the trials that contain ERBB2 V777L and breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 3 are phase 2 (3 open). *)
axiomatization where
  explanation_5: "∃x y z. Trials x ∧ ERBB2V777L y ∧ BreastCarcinoma z ∧ InclusionCriteria x y z ∧ Phase1or2 x ∧ Open x ∧ Phase2 x ∧ Open x"

theorem hypothesis:
  assumes asm: "Patient e x ∧ Treatment y ∧ (Neratinib y ∨ Lapatinib y) ∧ ClinicalTrial z ∧ ERBB2V777L z"
  (* Hypothesis: Patient may benefit from treatment with Neratinib or Lapatinib or may able to access a clinical trial for treatment of ERBB2 V777L *)
  shows "∃x y z e1 e2. ∃e. Patient e x ∧ Treatment y ∧ (Neratinib y ∨ Lapatinib y) ∧ ClinicalTrial z ∧ ERBB2V777L z ∧ ((Benefit e1 ∧ Agent e1 x ∧ Patient e1 y) ∨ (Access e2 ∧ Agent e2 x ∧ Patient e2 z))"
proof -
  (* From the premise, we have known information about the patient, treatment, and clinical trial. *)
  from asm have "Patient e x ∧ Treatment y ∧ (Neratinib y ∨ Lapatinib y) ∧ ClinicalTrial z ∧ ERBB2V777L z" by blast
  
  (* Explanation 1 provides a logical relation: Implies(A, C), which means Lapatinib and neratinib bind to the HER2 kinase domain implies patients with mutations in the HER2 kinase domain benefit. *)
  (* Since we have (Neratinib y ∨ Lapatinib y), we can infer that the patient may benefit from the treatment. *)
  then have "∃e1. Benefit e1 ∧ Agent e1 x ∧ Patient e1 y" sledgehammer
  
  (* Explanation 4 provides a logical relation: Implies(And(F, G), H), which means if ERBB2 V777L is an inclusion criterion in clinical trials for breast carcinoma and the trials are open, then patients with ERBB2 V777L may access open clinical trials. *)
  (* Since we have ERBB2V777L z and ClinicalTrial z, we can infer that the patient may access a clinical trial. *)
  then have "∃e2. Access e2 ∧ Agent e2 x ∧ Patient e2 z" <ATP>
  
  (* Combining both possibilities, we can conclude the hypothesis. *)
  then show ?thesis <ATP>
qed

end
